Antonieta Also Fontanet, B. Kostov, J. Benavent Àreu, M. Pinyol Martínez, Josep Miquel Sotoca Momblona, A. Benabarre Hernández, A. Sisó-Almirall
{"title":"Pilot psychotherapy program for the deprescription of benzodiazepines for anxiety disorders","authors":"Antonieta Also Fontanet, B. Kostov, J. Benavent Àreu, M. Pinyol Martínez, Josep Miquel Sotoca Momblona, A. Benabarre Hernández, A. Sisó-Almirall","doi":"10.5093/anyes2022a8","DOIUrl":null,"url":null,"abstract":"Introduction: The objective was to implement a pre-experimental pilot psychotherapy program for benzodiazepine deprescription in patients with anxiety disorders in primary care. Methods: Before-after clinical trial without a control group performed in two urban health centers. Patients aged 18-60 years with a diagnosis of anxiety disorder on benzodiazepine treatment were included. The program consisted of seven sessions of individual psychotherapy, and an individualized deprescription schedule. The Goldberg test and SF-12 questionnaire were administered in the first, third and final sessions. Results: Of the 123 patients included, 107 (87%) finished the study, of whom 93 (86.9%) were women, with a mean age of 44.7 years. Most had generalized anxiety disorder diagnosed in the past year. After completing the program, benzodiazepines were withdrawn in 54 out of 86 participants (62.8%); in 14 (16.3%) the dose was decreased, in 6 (7.0%) the dose was maintained and in 12 (13.9%) the dose was increased. There were significant improvements in the mental dimension of the SF-12 and the Goldberg test score. Conclusions: The intervention was useful in deprescibing benzodiazepines, reducing anxiety and improving the quality of life. Introducing such a program in primary care could allow a better approach to anxiety disorders, avoiding polypharmacy.","PeriodicalId":45616,"journal":{"name":"Ansiedad y Estres-Anxiety and Stress","volume":"53 1","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ansiedad y Estres-Anxiety and Stress","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5093/anyes2022a8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The objective was to implement a pre-experimental pilot psychotherapy program for benzodiazepine deprescription in patients with anxiety disorders in primary care. Methods: Before-after clinical trial without a control group performed in two urban health centers. Patients aged 18-60 years with a diagnosis of anxiety disorder on benzodiazepine treatment were included. The program consisted of seven sessions of individual psychotherapy, and an individualized deprescription schedule. The Goldberg test and SF-12 questionnaire were administered in the first, third and final sessions. Results: Of the 123 patients included, 107 (87%) finished the study, of whom 93 (86.9%) were women, with a mean age of 44.7 years. Most had generalized anxiety disorder diagnosed in the past year. After completing the program, benzodiazepines were withdrawn in 54 out of 86 participants (62.8%); in 14 (16.3%) the dose was decreased, in 6 (7.0%) the dose was maintained and in 12 (13.9%) the dose was increased. There were significant improvements in the mental dimension of the SF-12 and the Goldberg test score. Conclusions: The intervention was useful in deprescibing benzodiazepines, reducing anxiety and improving the quality of life. Introducing such a program in primary care could allow a better approach to anxiety disorders, avoiding polypharmacy.